{"id":27138,"date":"2022-08-04T16:57:00","date_gmt":"2022-08-04T08:57:00","guid":{"rendered":"https:\/\/flcube.com\/?p=27138"},"modified":"2025-02-17T17:01:53","modified_gmt":"2025-02-17T09:01:53","slug":"bloomage-biotech-terminates-medytox-pact-over-botox-supply-issues","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=27138","title":{"rendered":"Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues"},"content":{"rendered":"\n

China-based Bloomage Biotech (SHA: 688363<\/a>) announced that its wholly owned subsidiary, Gentix Limited, has issued a lawyer’s letter to South Korea-headquartered Medytox Inc. on July 29, 2022, seeking to terminate the agreement between the two companies related to Botox and other medical aesthetics products. The move comes after no products were provided for sale since the signing of the joint venture (JV) agreement.<\/p>\n\n\n\n

Background of the JV<\/strong>
Bloomage, which has been delisted, entered into a joint venture agreement with Medytox on May 7, 2015, to establish Medybloom Limited. The JV was tasked with developing, promoting, and marketing certain injectable botulinum toxin type A and other medical aesthetic products manufactured by Medytox in mainland China. In September 2019, Gentix acquired a 50% stake in Medybloom from Bloomage, obtaining Bloomage\u2019s rights under the JV agreement. Gentix and Medytox agreed to invest HKD17 million (USD2.16 million) each into Medybloom in March 2020.<\/p>\n\n\n\n

Regulatory Issues<\/strong>
In 2020, the Korean Ministry of Food and Drug Safety issued a series of executive orders for recalling, destroying, cancelling product approval procedures, and suspending manufacturing, sales, and use of a range of Medytox products, including botulinum toxin products. The botulinum toxin products registered by Medytox in China have been under review by the Center for Drug Evaluation (CDE) since November 11, 2019, with product registration procedures still pending. Gentix believes that the purpose of cooperation between the two parties cannot be realized in the foreseeable future. Bloomage stated that following the termination of the agreement with Medytox, it will not rule out seeking cooperation in other botulinum toxin products.<\/p>\n\n\n\n

Market Context<\/strong>
Statistics show that the domestic regular channel botulinum toxin market is valued at approximately RMB3.92 billion (USD580 million), a figure expected to reach RMB14 billion (USD2 billion) by 2025. South Korea\u2019s Daewoong Pharmaceutical Co., Ltd initiated a Phase III clinical study for its Botox Nabota in China in December 2019, with expectations to enter the market this year. Huadong Medicine secured exclusive agency rights to South Korea-based Jetema’s A type Botox in August 2020, while Fosun Pharma in-licensed Revance\u2019s Botox RT002 in December.<\/p>\n\n\n\n

Regulatory Environment<\/strong>
Due to its neurotoxin properties, botulinum toxin is strictly regulated. Currently, only four botulinum toxin products are approved in China: Allergan’s Botox (onabotulinumtoxinA), Ipsen’s Dysport, South Korea firm Hugel’s Letybo, and Lanzhou Institute of Biological Products’ Hengli (Botulinum Toxin Type A for Injection).-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[435,2276,519,100,2275],"class_list":["post-27138","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-allergan-aesthetics","tag-bloomage-biotech","tag-ipsen-s-a","tag-medical-aesthetics","tag-sha-688363"],"yoast_head":"\nBloomage Biotech Terminates Medytox Pact Over Botox Supply Issues - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued a lawyer's letter to South Korea-headquartered Medytox Inc. on July 29, 2022, seeking to terminate the agreement between the two companies related to Botox and other medical aesthetics products. The move comes after no products were provided for sale since the signing of the joint venture (JV) agreement.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=27138\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=27138\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-04T08:57:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-17T09:01:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27138#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27138\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues\",\"datePublished\":\"2022-08-04T08:57:00+00:00\",\"dateModified\":\"2025-02-17T09:01:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27138\"},\"wordCount\":398,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Allergan Aesthetics\",\"Bloomage Biotech\",\"Ipsen S.A.\",\"Medical aesthetics\",\"SHA: 688363\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=27138#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27138\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=27138\",\"name\":\"Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-08-04T08:57:00+00:00\",\"dateModified\":\"2025-02-17T09:01:53+00:00\",\"description\":\"China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued a lawyer's letter to South Korea-headquartered Medytox Inc. on July 29, 2022, seeking to terminate the agreement between the two companies related to Botox and other medical aesthetics products. The move comes after no products were provided for sale since the signing of the joint venture (JV) agreement.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27138#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=27138\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27138#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues - Insight, China's Pharmaceutical Industry","description":"China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued a lawyer's letter to South Korea-headquartered Medytox Inc. on July 29, 2022, seeking to terminate the agreement between the two companies related to Botox and other medical aesthetics products. The move comes after no products were provided for sale since the signing of the joint venture (JV) agreement.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=27138","og_locale":"en_US","og_type":"article","og_title":"Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=27138","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-08-04T08:57:00+00:00","article_modified_time":"2025-02-17T09:01:53+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=27138#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=27138"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues","datePublished":"2022-08-04T08:57:00+00:00","dateModified":"2025-02-17T09:01:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=27138"},"wordCount":398,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Allergan Aesthetics","Bloomage Biotech","Ipsen S.A.","Medical aesthetics","SHA: 688363"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=27138#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=27138","url":"https:\/\/flcube.com\/?p=27138","name":"Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-08-04T08:57:00+00:00","dateModified":"2025-02-17T09:01:53+00:00","description":"China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued a lawyer's letter to South Korea-headquartered Medytox Inc. on July 29, 2022, seeking to terminate the agreement between the two companies related to Botox and other medical aesthetics products. The move comes after no products were provided for sale since the signing of the joint venture (JV) agreement.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=27138#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=27138"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=27138#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/27138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=27138"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/27138\/revisions"}],"predecessor-version":[{"id":27139,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/27138\/revisions\/27139"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=27138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=27138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=27138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}